article thumbnail

STAT+: Pharmalittle: We’re reading about Amgen suing Colorado over drug price caps, abortion pills, and more

STAT

Novo Nordisk plans to seek coverage by Germany’s public health insurance scheme for the use of its Wegovy drug to cut the risk of strokes and heart attacks, if the extended indication wins European approval , Reuters notes. Meanwhile, the Biosecure Act, designed to reduce U.S.

article thumbnail

Is India capable of ensuring equitable access to biopharmaceuticals?

Express Pharma

To help financially weak citizens gain access to affordable healthcare, the Pradhan Mantri Jan Arogya Yojana (PMJAY) was launched in 2018, providing about 500 million Indians with a ₹5 lakh family health insurance cover that include coverage for 1,400 medical procedures as well as critical diseases like prostate cancer.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

How early planning leads to successful market access and drug launch in Europe

Pharmaceutical Technology

Launching a new drug can be a risky business, with regulatory approval no guarantee that private, commercial, and government-funded insurers will reimburse it. In Europe, the pricing and reimbursement (P&R) of pharmaceuticals is governed by individual member states.

article thumbnail

Drug Manufacturers’ 340B Restrictions Generate New Round Of Media Scrutiny & Criticism

Proxsys Rx

“Don’t believe drug companies: 340B is a program worth saving” On Tuesday, August 8, The Hill published a guest editorial (title above) by John Hassell — national director of advocacy at the AIDS Healthcare Foundation (AHF). First, start with presenting drug company-funded research as if it is non-biased. margins vs. 7.7%